{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T09:32:53Z","timestamp":1782120773611,"version":"3.54.5"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T00:00:00Z","timestamp":1640563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","award":["NCC-1911274-1"],"award-info":[{"award-number":["NCC-1911274-1"]}],"id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>It remains inconclusive whether the use of oral contraceptives (OCs) alters the risks of breast or ovarian cancer in women with a breast cancer susceptibility gene 1 (BRCA1) or breast cancer susceptibility gene 2 (BRCA2) mutation. We investigated the association between OC use and the risks of breast or ovarian cancer in this group by using a meta-analysis. PubMed and EMBASE were searched using keywords until February 2021 to identify relevant studies that evaluated the association between OC ever use and the risks of breast or ovarian cancer in women with a BRCA1 or BRCA2 mutation. Twelve studies for breast cancer and eight studies for ovarian cancer were identified. In the random-effects meta-analysis, the ever use of OCs was significantly associated with an increased risk of breast cancer [odds ratio (OR), relative risk (RR) or hazard ratio (HR) = 1.24; 95% confidence interval (CI) 1.08\u20131.41] and a decreased risk of ovarian cancer (OR\/RR\/HR = 0.53, 95% CI 0.41\u20130.67). Consistent findings were observed when BRCA1 and BRCA2 mutation carriers were analyzed separately. The increased risk of breast cancer was observed only in the long-term (&amp;gt;5 years) users of OCs, while the decreased risk of ovarian cancer was observed regardless of the duration of OC use. The current study suggests that the ever use of OCs in BRCA mutation carriers is significantly associated with an increased risk of breast cancer and a decreased risk of ovarian cancer. Therefore, the use of OCs as chemoprevention of ovarian cancer should be cautious in BRCA mutation carriers.<\/jats:p>","DOI":"10.1093\/carcin\/bgab107","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T12:07:52Z","timestamp":1635768472000},"page":"231-242","source":"Crossref","is-referenced-by-count":22,"title":["Oral contraceptives and risk of breast cancer and ovarian cancer in women with a <i>BRCA1<\/i> or <i>BRCA2<\/i> mutation: a meta-analysis of observational studies"],"prefix":"10.1093","volume":"43","author":[{"given":"Junli","family":"Park","sequence":"first","affiliation":[{"name":"Center for Cancer Prevention and Detection, Hospital, National Cancer Center, Goyang, Republic of Korea"},{"name":"Department of Family Medicine, Myongji Hospital, Goyang, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Cancer Control & Policy, National Cancer Control Institute, National Cancer Center, Goyang, Republic of Korea"},{"name":"Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Jung","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Cancer Control & Policy, National Cancer Control Institute, National Cancer Center, Goyang, Republic of Korea"},{"name":"Department of Cancer Control and Population Health, National Cancer Center Graduate School of Cancer Science and Policy, Goyang, Republic of Korea"},{"name":"Department of Family Medicine, Hospital, National Cancer Center, Goyang, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myong Cheol","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Cancer Control and Population Health, National Cancer Center Graduate School of Cancer Science and Policy, Goyang, Republic of Korea"},{"name":"Center for Gynecologic Cancer and Center for Clinical Trial, Hospital, National Cancer Center, Goyang, Republic of Korea"},{"name":"Division of Tumor Immunology, Rare & Pediatric Cancer Branch and Immuno-oncology Branch, Division of Rare and Refractory Cancer, Research Institute, National Cancer Center, Goyang, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8911-1345","authenticated-orcid":false,"given":"Seung-Kwon","family":"Myung","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Hospital, National Cancer Center, Goyang, Republic of Korea"},{"name":"Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Republic of Korea"},{"name":"Cancer Epidemiology Branch, Division of Cancer Data Science, Research Institute, National Cancer Center, Goyang, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,12,27]]},"reference":[{"key":"2022042513020058500_CIT0001","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.","volume":"302","author":"King","year":"2003","journal-title":"Science"},{"key":"2022042513020058500_CIT0002","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"J. Am. Med. Assoc."},{"key":"2022042513020058500_CIT0003","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies.","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"2022042513020058500_CIT0004","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(06)70585-X","article-title":"Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.","volume":"7","author":"Domchek","year":"2006","journal-title":"Lancet Oncol."},{"key":"2022042513020058500_CIT0005","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa020119","article-title":"Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.","volume":"346","author":"Kauff","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"2022042513020058500_CIT0006","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1158\/1940-6207.CAPR-21-0141","article-title":"Bilateral salpingo-oophorectomy and breast cancer risk for BRCA1 and BRCA2 mutation carriers: assessing the evidence.","volume":"14","author":"Conduit","year":"2021","journal-title":"Cancer Prev. Res. (Phila)."},{"key":"2022042513020058500_CIT0007","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0361-090X(02)00004-1","article-title":"Oral contraceptives and risk of familial breast cancer.","volume":"26","author":"Heimdal","year":"2002","journal-title":"Cancer Detect. Prev."},{"key":"2022042513020058500_CIT0008","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10549-005-9051-5","article-title":"Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland.","volume":"95","author":"Gronwald","year":"2006","journal-title":"Breast Cancer Res. Treat."},{"key":"2022042513020058500_CIT0009","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s10549-009-0455-5","article-title":"Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study.","volume":"120","author":"Figueiredo","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"2022042513020058500_CIT0010","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1200\/JCO.2007.11.1179","article-title":"Oral contraceptives and breast cancer risk in the International BRCA1\/2 Carrier Cohort Study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group.","volume":"25","author":"Brohet","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"2022042513020058500_CIT0011","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1158\/1055-9965.EPI-14-0884","article-title":"Breast cancer risk associated with estrogen exposure and truncating mutation location in BRCA1\/2 carriers.","volume":"24","author":"Lecarpentier","year":"2015","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"2022042513020058500_CIT0012","doi-asserted-by":"crossref","first-page":"102110","DOI":"10.18632\/oncotarget.22193","article-title":"Reproductive factors as risk modifiers of breast cancer in BRCA mutation carriers and high-risk non-carriers.","volume":"8","author":"Park","year":"2017","journal-title":"Oncotarget"},{"key":"2022042513020058500_CIT0013","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1200\/JCO.2013.48.9021","article-title":"Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis.","volume":"31","author":"Moorman","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"2022042513020058500_CIT0014","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ygyno.2013.12.014","article-title":"Risk management options elected by women after testing positive for a BRCA mutation.","volume":"132","author":"Garcia","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"2022042513020058500_CIT0015","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s40495-018-0133-6","article-title":"The chemoprevention of ovarian cancer: the need and the options.","volume":"4","author":"Kathawala","year":"2018","journal-title":"Curr. Pharmacol. Rep."},{"key":"2022042513020058500_CIT0016","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1056\/NEJMoa1700732","article-title":"Contemporary hormonal contraception and the risk of breast cancer.","volume":"377","author":"M\u00f8rch","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"2022042513020058500_CIT0017","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cct.2006.04.004","article-title":"Random-effects model for meta-analysis of clinical trials: an update.","volume":"28","author":"DerSimonian","year":"2007","journal-title":"Contemp. Clin. Trials"},{"key":"2022042513020058500_CIT0018","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis.","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat. Med."},{"key":"2022042513020058500_CIT0019","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/sim.698","article-title":"A comparison of methods to detect publication bias in meta-analysis.","volume":"20","author":"Macaskill","year":"2001","journal-title":"Stat. Med."},{"key":"2022042513020058500_CIT0020","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/jnci\/94.23.1773","article-title":"Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.","volume":"94","author":"Narod","year":"2002","journal-title":"J. Natl Cancer Inst."},{"key":"2022042513020058500_CIT0021","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1158\/1055-9965.EPI-06-0258","article-title":"BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50.","volume":"15","author":"Haile","year":"2006","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"2022042513020058500_CIT0022","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1158\/1055-9965.EPI-08-0396","article-title":"Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1\/2 mutation carriers and noncarriers: results from a population-based study.","volume":"17","author":"Lee","year":"2008","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"2022042513020058500_CIT0023","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s10549-011-1509-z","article-title":"Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation.","volume":"129","author":"Bernholtz","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"2022042513020058500_CIT0024","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10549-013-2823-4","article-title":"Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers.","volume":"143","author":"Kotsopoulos","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"2022042513020058500_CIT0025","doi-asserted-by":"crossref","first-page":"pky023","DOI":"10.1093\/jncics\/pky023","article-title":"Oral contraceptive use and breast cancer risk: retrospective and prospective analyses from a BRCA1 and BRCA2 mutation carrier cohort study.","volume":"2","author":"Schrijver","year":"2018","journal-title":"JNCI Cancer Spectr."},{"key":"2022042513020058500_CIT0026","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/sj.bjc.6602239","article-title":"Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations.","volume":"91","author":"Whittemore","year":"2004","journal-title":"Br. J. Cancer"},{"key":"2022042513020058500_CIT0027","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S1470-2045(06)70983-4","article-title":"Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case\u2013control study.","volume":"8","author":"McLaughlin","year":"2007","journal-title":"Lancet. Oncol."},{"key":"2022042513020058500_CIT0028","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1158\/1055-9965.EPI-08-0546","article-title":"Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1\/2 Carrier Cohort Study.","volume":"18","author":"Antoniou","year":"2009","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"2022042513020058500_CIT0029","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ygyno.2009.06.012","article-title":"Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers.","volume":"115","author":"Vicus","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"2022042513020058500_CIT0030","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/ijc.29386","article-title":"Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.","volume":"137","author":"Kotsopoulos","year":"2015","journal-title":"Int. J. Cancer"},{"key":"2022042513020058500_CIT0031","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.fertnstert.2015.02.011","article-title":"Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers.","volume":"103","author":"Perri","year":"2015","journal-title":"Fertil. Steril."},{"key":"2022042513020058500_CIT0032","doi-asserted-by":"crossref","first-page":"51.e1","DOI":"10.1016\/j.ajog.2021.01.014","article-title":"Oral contraceptive use and ovarian cancer risk for BRCA1\/2 mutation carriers: an international cohort study.","volume":"225","author":"Schrijver","year":"2021","journal-title":"Am. J. Obstet. Gynecol."},{"key":"2022042513020058500_CIT0033","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nrclinonc.2011.110","article-title":"Hormone replacement therapy and the risk of breast cancer.","volume":"8","author":"Narod","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2022042513020058500_CIT0034","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature09027","article-title":"Control of mammary stem cell function by steroid hormone signalling.","volume":"465","author":"Asselin-Labat","year":"2010","journal-title":"Nature"},{"key":"2022042513020058500_CIT0035","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nature09091","article-title":"Progesterone induces adult mammary stem cell expansion.","volume":"465","author":"Joshi","year":"2010","journal-title":"Nature"},{"key":"2022042513020058500_CIT0036","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nature09495","article-title":"RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis.","volume":"468","author":"Gonzalez-Suarez","year":"2010","journal-title":"Nature"},{"key":"2022042513020058500_CIT0037","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nature09387","article-title":"Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer.","volume":"468","author":"Schramek","year":"2010","journal-title":"Nature"},{"key":"2022042513020058500_CIT0038","doi-asserted-by":"crossref","first-page":"641","DOI":"10.15252\/embj.201490434","article-title":"Progesterone and Wnt4 control mammary stem cells via myoepithelial crosstalk.","volume":"34","author":"Rajaram","year":"2015","journal-title":"EMBO J."},{"key":"2022042513020058500_CIT0039","first-page":"292","article-title":"Incessant ovulation and ovarian cancer\u2014a hypothesis re-visited.","volume":"5","author":"Fathalla","year":"2013","journal-title":"Facts Views Vis. Obgyn"},{"key":"2022042513020058500_CIT0040","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1530\/ERC-11-0107","article-title":"The impact of ovulation on fallopian tube epithelial cells: evaluating three hypotheses connecting ovulation and serous ovarian cancer.","volume":"18","author":"King","year":"2011","journal-title":"Endocr. Relat. Cancer"},{"key":"2022042513020058500_CIT0041","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0303-7207(01)00675-X","article-title":"Steroid hormonal regulation of proliferative, p53 tumor suppressor, and apoptotic responses of sheep ovarian surface epithelial cells.","volume":"186","author":"Murdoch","year":"2002","journal-title":"Mol. Cell. Endocrinol."},{"key":"2022042513020058500_CIT0042","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1158\/0008-5472.CAN-19-2850","article-title":"The risk of ovarian cancer increases with an increase in the lifetime number of ovulatory cycles: an analysis from the Ovarian Cancer Cohort Consortium (OC3).","volume":"80","author":"Trabert","year":"2020","journal-title":"Cancer Res."},{"key":"2022042513020058500_CIT0043","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S0140-6736(96)90806-5","article-title":"Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies","volume":"347","author":"Collaborative Group on Hormonal Factors in Breast C.","year":"1996","journal-title":"Lancet"},{"key":"2022042513020058500_CIT0044","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(08)60167-1","article-title":"Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls","volume":"371","author":"Beral","year":"2008","journal-title":"Lancet"},{"key":"2022042513020058500_CIT0045","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1016\/j.ejca.2010.04.018","article-title":"Oral contraceptive use and breast or ovarian cancer risk in BRCA1\/2 carriers: a meta-analysis.","volume":"46","author":"Iodice","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"2022042513020058500_CIT0046","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1586\/era.11.38","article-title":"Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis.","volume":"11","author":"Cibula","year":"2011","journal-title":"Expert Rev. Anticancer Ther."},{"key":"2022042513020058500_CIT0047","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/1055-9965.EPI-11-0775","article-title":"Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1\/2 (CIMBA).","volume":"21","author":"Mavaddat","year":"2012","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"2022042513020058500_CIT0048","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3892\/mco.2017.1259","article-title":"Association between oral contraceptive use as a risk factor and triple-negative breast cancer: a systematic review and meta-analysis.","volume":"7","author":"Li","year":"2017","journal-title":"Mol. Clin. Oncol."}],"container-title":["Carcinogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/carcin\/advance-article-pdf\/doi\/10.1093\/carcin\/bgab107\/42547191\/bgab107.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/carcin\/article-pdf\/43\/3\/231\/43447848\/bgab107.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/carcin\/article-pdf\/43\/3\/231\/43447848\/bgab107.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T13:02:52Z","timestamp":1650891772000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/carcin\/article\/43\/3\/231\/6484912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,27]]},"references-count":48,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,12,27]]},"published-print":{"date-parts":[[2022,4,25]]}},"URL":"https:\/\/doi.org\/10.1093\/carcin\/bgab107","relation":{},"ISSN":["0143-3334","1460-2180"],"issn-type":[{"value":"0143-3334","type":"print"},{"value":"1460-2180","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3,1]]},"published":{"date-parts":[[2021,12,27]]}}}